CCR RNAi Initiative: Overview

基因沉默组（GSS）遗传学分支，旨在成为CCR中具有特定专业知识的小组，研究和应用RNAi在哺乳动物细胞中的应用。RNAi领域的科学和临床发展正在迅速影响我们对RNA沉默机制在控制正常和疾病相关基因表达（包括癌症）中的作用的理解。此外，利用RNAi机制的技术发展已经发展到基因功能分析和新模型系统的开发。最近，基于RNAi的分析已被用于提高对药物：靶标相互作用和靶标识别的理解，这些策略现在正被扩展到能够进行大规模筛选，可能达到全基因组。除了我们基于项目的研究（见其他项目报告），我们在协助和培训CCR研究人员使用RNAi进行基因功能分析方面发挥了广泛的作用，包括但不限于培训研究人员和博士后在RNAi分析技术的不同方面，共享协议和RNAi表征数据（见下文），以及直接合作。为了开发我们的第一个大规模RNAi效应物资源，GSS部门负责人Caplen博士已经在基因沉默部门，遗传部门，CCR和Qiagen公司之间达成了一项研究合作协议（RCA #2-18668-05, AKA MTA 18668），该协议于2007年续签了三年。我们也越来越多地关注RNAi筛选方法的使用，并且已经启动了许多独立和协作的RNAi筛选。

The Gene Silencing Section, (GSS) Genetics Branch, aims to be a group with specific expertise within CCR for the study and application of RNAi in mammalian cells. The scientific and clinical developments in the field of RNAi are rapidly impacting our understanding of the role of RNA silencing mechanisms on the control of normal and disease related gene expression, including cancer. Further, technological developments utilizing the RNAi mechanism have been developed for the analysis of gene function and the development of new model systems. More recently RNAi based analysis has been used for improved understanding of drug: target interactions and target identification, and these strategies are now being scaled to enable large scale screening, potentially up to whole genome. In addition to our project based research (see other project reports) we have played an extensive role in assisting and training CCR investigators in the use of RNAi for gene function analysis including, though not limited to, the training of Investigators and Post Doctoral Fellows in different aspects of RNAi analysis technologies, the sharing of protocols and RNAi characterization data (see below), as well as direct collaboration. To develop our first large scale RNAi effector resource Dr. Caplen, the GSS section head, has pursued a research collaboration agreement (RCA #2-18668-05, AKA MTA 18668) between the Gene Silencing Section, Genetics Branch, CCR and Qiagen Inc that was renewed in 2007 for a further three years. We are also increasingly focusing our efforts on the use of RNAi screening approaches and a number of independent and collaborative RNAi screens have been initiated.